AbbVie said it expects its Q3 2024 results to include acquired IPR&D and milestones expense of $82 million on a pre-tax basis. The company said this represents an unfavorable impact of $0.04 to both GAAP and adjusted non-GAAP diluted earnings per share.

1. 01

   AbbVie said it expects its Q3 2024 results to include acquired IPR&D and milestones expense of $82 million on a pre-tax basis. The company said this represents an unfavorable impact of $0.04 to both GAAP and adjusted non-GAAP diluted earnings per share.

2. 02

   AbbVie said its adjusted diluted earnings per share outlook for Q3 2024, including the Q3 acquired IPR&D and milestones expense, is $2.88 to $2.92. The prior outlook, which excluded this expense, was $2.92 to $2.96 per share.

3. 03

   AbbVie said its adjusted diluted earnings per share outlook for full-year 2024, including the Q3 acquired IPR&D and milestones expense, is $10.67 to $10.87. The prior outlook, announced on August 1, excluded the Q3 expense and was $10.71 to $10.91 per share.

4. 04

   AbbVie said its full-year 2024 acquired IPR&D and milestones expense, including the Q3 expense, is $1,183 million. It said it does not forecast expense that may be incurred after Q3, as it cannot reliably forecast such expense.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.